cibisatamab
mAbexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 30, 2014 (NCT02324257)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CEACAM5 inhibitor
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, passive
CEACAM5 immunity, passive
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298091 ↗
Also known as
- ro6958688
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04826003 | Phase 1/Phase 2 (Phase 2) | Jul 21, 2021 | Roche |
| NCT03866239 | Phase 1 | May 7, 2019 | Roche |
| NCT03337698 | Phase 1/Phase 2 (Phase 2) | Dec 27, 2017 | Roche |
| NCT02650713 | Phase 1 | Jan 1, 2016 | Roche |
| NCT02324257 | Phase 1 | Dec 30, 2014 | Roche |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 5 | 5 | 2 | 2014 |
1 organizations
Page 1 / 1